LT4705B - Nauji guanidininiai imitatoriai kaip xa faktoriaus inhibitoriai - Google Patents
Nauji guanidininiai imitatoriai kaip xa faktoriaus inhibitoriai Download PDFInfo
- Publication number
- LT4705B LT4705B LT99-147A LT99147A LT4705B LT 4705 B LT4705 B LT 4705B LT 99147 A LT99147 A LT 99147A LT 4705 B LT4705 B LT 4705B
- Authority
- LT
- Lithuania
- Prior art keywords
- pyrazole
- aminocarbonyl
- aminobenzisoxazol
- biphen
- fluoro
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
- C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87888497A | 1997-06-19 | 1997-06-19 |
Publications (2)
Publication Number | Publication Date |
---|---|
LT99147A LT99147A (en) | 2000-04-25 |
LT4705B true LT4705B (lt) | 2000-09-25 |
Family
ID=25373029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LT99-147A LT4705B (lt) | 1997-06-19 | 1999-12-17 | Nauji guanidininiai imitatoriai kaip xa faktoriaus inhibitoriai |
Country Status (31)
Country | Link |
---|---|
EP (1) | EP0991638B1 (fr) |
JP (1) | JP4319255B2 (fr) |
KR (1) | KR100546522B1 (fr) |
CN (1) | CN100358888C (fr) |
AR (1) | AR015391A1 (fr) |
AT (1) | ATE302198T1 (fr) |
AU (1) | AU756755B2 (fr) |
BR (1) | BR9810137A (fr) |
CA (1) | CA2291442A1 (fr) |
DE (1) | DE69831238T2 (fr) |
DK (1) | DK0991638T3 (fr) |
EA (1) | EA003210B1 (fr) |
EE (1) | EE04153B1 (fr) |
ES (1) | ES2244064T3 (fr) |
HK (1) | HK1028606A1 (fr) |
HR (1) | HRP980333A2 (fr) |
HU (1) | HUP0002686A3 (fr) |
IL (2) | IL133525A0 (fr) |
LT (1) | LT4705B (fr) |
LV (1) | LV12496B (fr) |
MY (1) | MY119820A (fr) |
NO (1) | NO318359B1 (fr) |
NZ (1) | NZ502370A (fr) |
PL (1) | PL192941B1 (fr) |
RO (1) | RO120543B1 (fr) |
SI (1) | SI20160B (fr) |
SK (1) | SK285685B6 (fr) |
TW (1) | TW544453B (fr) |
UA (1) | UA57780C2 (fr) |
WO (1) | WO1998057951A1 (fr) |
ZA (1) | ZA985247B (fr) |
Families Citing this family (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
US6313122B1 (en) | 1997-06-26 | 2001-11-06 | Eli Lilly And Company | Antithrombotic agents |
DE69830504T2 (de) | 1997-06-26 | 2006-03-16 | Eli Lilly And Co., Indianapolis | Antithrombotische mitteln |
IL133625A0 (en) | 1997-06-26 | 2001-04-30 | Lilly Co Eli | Antithrombotic agents |
WO1999050255A2 (fr) | 1998-03-27 | 1999-10-07 | Du Pont Pharmaceuticals Company | Pyrazolines et triazolines disubstituees, utilisees en tant qu'inhibiteurs du facteur xa |
AU1616600A (en) * | 1998-11-12 | 2000-05-29 | Eli Lilly And Company | Aminobenzisoxazole compounds and libraries thereof |
AU3127900A (en) * | 1998-12-23 | 2000-07-31 | Du Pont Pharmaceuticals Company | Thrombin or factor xa inhibitors |
WO2000051998A1 (fr) | 1999-03-02 | 2000-09-08 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes utiles en tant qu'inhibiteurs reversibles de la cathepsine s |
ES2197092T3 (es) | 1999-04-02 | 2004-01-01 | Bristol-Myers Squibb Pharma Company | Sulfonil arilos como inhibidores del factor xa. |
ATE306481T1 (de) | 1999-05-12 | 2005-10-15 | Ortho Mcneil Pharm Inc | Pyrazolecarboxamide zur behandlung von fettleibigkeit und anderen erkrankungen |
WO2000076971A2 (fr) | 1999-06-14 | 2000-12-21 | Eli Lilly And Company | Composes |
WO2001005784A1 (fr) * | 1999-07-16 | 2001-01-25 | Bristol-Myers Squibb Pharma Company | Composes heterobicycliques contenant de l'azote et utilises en tant qu'inhibiteurs du facteur xa |
DE19937537A1 (de) * | 1999-08-09 | 2001-03-08 | Gruenenthal Gmbh | Substituierte 2-Dialkylaminoalkylbiphenyl-Derivate |
US6420364B1 (en) | 1999-09-13 | 2002-07-16 | Boehringer Ingelheim Pharmaceuticals, Inc. | Compound useful as reversible inhibitors of cysteine proteases |
US6720317B1 (en) * | 1999-09-17 | 2004-04-13 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
US6632815B2 (en) * | 1999-09-17 | 2003-10-14 | Millennium Pharmaceuticals, Inc. | Inhibitors of factor Xa |
US6329527B1 (en) | 1999-10-21 | 2001-12-11 | Bristol-Myers Squibb Pharma Company | Synthesis of 1,3,5-trisubstituted pyrazoles |
US6407256B1 (en) | 1999-11-03 | 2002-06-18 | Bristol Myers Squibb Co | Cyano-pyrrole, cyano-imidazole, cyano-pyrazole, and cyano-triazole compounds as factor Xa inhibitors |
EP1263754A1 (fr) * | 2000-02-01 | 2002-12-11 | Millennium Pharmaceuticals, Inc. | INHIBITEURS INDALONE ET BENZIMIDAZOLONE DU FACTEUR Xa |
JP2004501913A (ja) | 2000-06-23 | 2004-01-22 | ブリストル−マイヤーズ スクイブ ファーマ カンパニー | ヘテロアリール−フェニル置換Xa因子阻害剤 |
AU2001268712A1 (en) | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Company | 1 - (heteroaryl-phenyl) - condensed pyrazol derivatives as factor Xa inhibitors |
US6541639B2 (en) | 2000-07-26 | 2003-04-01 | Bristol-Myers Squibb Pharma Company | Efficient ligand-mediated Ullmann coupling of anilines and azoles |
AU2001292612A1 (en) | 2000-09-22 | 2002-04-02 | Bristol-Myers Squibb Pharma Company | Efficient process for the preparation of a factor XA inhibitor |
TWI331526B (en) | 2001-09-21 | 2010-10-11 | Bristol Myers Squibb Pharma Co | Lactam-containing compounds and derivatives thereof as factor xa inhibitors |
CN104744461A (zh) | 2001-09-21 | 2015-07-01 | 百时美施贵宝公司 | 含有内酰胺的化合物及其衍生物作为Xa因子的抑制剂 |
US7030141B2 (en) * | 2001-11-29 | 2006-04-18 | Christopher Franklin Bigge | Inhibitors of factor Xa and other serine proteases involved in the coagulation cascade |
TW200303309A (en) * | 2001-12-04 | 2003-09-01 | Bristol Myers Squibb Co | Novel n-[4-(1h-imidazol-1-yl)-2-fluorophenyl]-3-trifluoromethyl)-1h-pyrazole-5-carboxamides as factor Xa inhibitors |
TW200302225A (en) | 2001-12-04 | 2003-08-01 | Bristol Myers Squibb Co | Substituted amino methyl factor Xa inhibitors |
WO2003048081A2 (fr) | 2001-12-04 | 2003-06-12 | Bristol-Myers Squibb Company | Glycinamides en tant qu'inhibiteurs du facteur xa |
WO2003099276A1 (fr) | 2002-05-10 | 2003-12-04 | Bristol-Myers Squibb Company | Derives cycloalkyles 1,1-disubstitues utilises en tant qu'inhibiteurs du facteur xa |
DE10229070A1 (de) * | 2002-06-28 | 2004-01-15 | Merck Patent Gmbh | Phenylderivate 5 |
WO2004031177A1 (fr) * | 2002-09-30 | 2004-04-15 | Banyu Pharmaceutical Co., Ltd. | Derive de 2-aminobenzimidazole |
WO2004031143A2 (fr) * | 2002-10-02 | 2004-04-15 | Bristol-Myers Squibb Company | Combinaison d'un inhibiteur de facteur x$g(a) et de clopidogrel |
US7319109B2 (en) | 2002-11-22 | 2008-01-15 | Smith Kline Beecham Corporation | Farnesoid X receptor agonists |
CN100513398C (zh) | 2002-12-03 | 2009-07-15 | Axys药物公司 | 作为因子viia抑制剂的2-(2-羟基联苯-3-基)-1h-苯并咪唑-5-甲脒衍生物 |
US7122557B2 (en) | 2003-03-18 | 2006-10-17 | Bristol-Myers Squibb Company | Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors |
US7550499B2 (en) | 2004-05-12 | 2009-06-23 | Bristol-Myers Squibb Company | Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
CN101083985A (zh) | 2004-09-21 | 2007-12-05 | 幸讬制药公司 | 用于炎症及免疫相关用途的化合物 |
MX2007008434A (es) | 2005-01-19 | 2007-07-25 | Squibb Bristol Myers Co | Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos. |
WO2007002584A1 (fr) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Mimetiques lineaires de l’uree antagonistes du recepteur p2y1, utilises dans le traitement des troubles thrombotiques |
EP1896466B1 (fr) | 2005-06-27 | 2011-04-13 | Bristol-Myers Squibb Company | Antagonistes heterocycliques a liaison n du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques |
WO2007002634A1 (fr) | 2005-06-27 | 2007-01-04 | Bristol-Myers Squibb Company | Antagonistes carbocycliques et heherocycliques du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques |
EP1899299B1 (fr) | 2005-06-27 | 2010-10-20 | Bristol-Myers Squibb Company | Antagonistes cycliques a liaison c du recepteur p2y1, utiles pour traiter des etats pathologiques thrombotiques |
EP1928866A1 (fr) | 2005-09-05 | 2008-06-11 | Ranbaxy Laboratories Limited | Indazoles substitues utilises en tant qu'inhibiteurs de phosphodiesterase de type-iv |
US7915286B2 (en) | 2005-09-16 | 2011-03-29 | Ranbaxy Laboratories Limited | Substituted pyrazolo [3,4-b] pyridines as phosphodiesterase inhibitors |
WO2007031977A2 (fr) | 2005-09-16 | 2007-03-22 | Ranbaxy Laboratories Limited | Inhibiteurs de la phosphodiesterase |
NZ568595A (en) | 2005-12-14 | 2010-04-30 | Bristol Myers Squibb Co | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor Xla inhibitors |
US7960569B2 (en) | 2006-10-17 | 2011-06-14 | Bristol-Myers Squibb Company | Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions |
US8410155B2 (en) | 2006-12-15 | 2013-04-02 | Bristol-Myers Squibb Company | Arylpropionamide, arylacrylamide, arylpropynamide, or arylmethylurea analogs as factor XIA inhibitors |
PE20081775A1 (es) | 2006-12-20 | 2008-12-18 | Bristol Myers Squibb Co | Compuestos macrociclicos como inhibidores del factor viia |
CN103497185A (zh) | 2007-03-14 | 2014-01-08 | 兰贝克赛实验室有限公司 | 用作磷酸二酯酶抑制剂的吡唑并(3,4-b)吡啶衍生物 |
MY153427A (en) | 2007-04-23 | 2015-02-13 | Sanofi Aventis | Quinoline-carboxamide derivatives as p2y12 antagonists |
EP2186804B1 (fr) * | 2007-08-10 | 2015-06-17 | Nippon Soda Co., Ltd. | Composé hétérocyclique contenant de l'azote et agent de lutte contre les animaux nuisibles |
EP2238128B1 (fr) | 2007-12-26 | 2012-08-22 | Sanofi | Pyrazole-carboxamides hétérocycliques utilisés en tant qu'antagonistes du récepteur p2y12 |
CA2789622C (fr) | 2010-02-11 | 2018-04-03 | Bristol-Myers Squibb Company | Macrocycles utilises en tant qu'inhibiteurs du facteur xia |
WO2012098089A1 (fr) | 2011-01-19 | 2012-07-26 | Bayer Pharma Aktiengesellschaft | Protéines de liaison à des inhibiteurs de facteurs de coagulation |
TW201319068A (zh) | 2011-08-05 | 2013-05-16 | 必治妥美雅史谷比公司 | 作為xia因子抑制劑之環狀p1接合劑 |
TW201311689A (zh) | 2011-08-05 | 2013-03-16 | 必治妥美雅史谷比公司 | 作為因子xia抑制劑之新穎巨環化合物 |
US9079929B2 (en) | 2011-10-14 | 2015-07-14 | Bristol-Myers Squibb Company | Substituted tetrahydroisoquinoline compounds as factor XIa inhibitors |
SG11201401384UA (en) | 2011-10-14 | 2014-09-26 | Bristol Myers Squibb Co | Substituted tetrahydroisoquinoline compounds as factor xia inhibitors |
US9108951B2 (en) | 2011-10-14 | 2015-08-18 | Bristol-Myers Squibb Company | Substituted 5,6,7,8-tetrahydro-1,6-naphthyridines as factor XIa inhibitors |
KR20150038369A (ko) | 2012-08-03 | 2015-04-08 | 브리스톨-마이어스 스큅 컴퍼니 | 인자 XIa 억제제로서의 디히드로피리돈 P1 |
WO2014022767A1 (fr) | 2012-08-03 | 2014-02-06 | Bristol-Myers Squibb Company | Récepteurs p1 de la dihydropyridone en tant qu'inhibiteurs du facteur xia |
CA2891412A1 (fr) | 2012-11-20 | 2014-05-30 | Vertex Pharmaceuticals Incorporated | Composes utiles comme inhibiteurs de l'indoleamine 2,3-dioxygenase |
US9738655B2 (en) | 2013-03-25 | 2017-08-22 | Bristol-Myers Squibb Company | Tetrahydroisoquinolines containing substituted azoles as factor XIa inhibitors |
IL307212A (en) | 2014-01-31 | 2023-11-01 | Bristol Myers Squibb Co | Macrocyclines with P2' heterocyclic groups as factor XIA inhibitors |
NO2760821T3 (fr) | 2014-01-31 | 2018-03-10 | ||
KR20230042384A (ko) * | 2014-03-07 | 2023-03-28 | 바이오크리스트파마슈티컬즈,인코포레이티드 | 인간 혈장 칼리크레인 저해제 |
NO2721243T3 (fr) | 2014-10-01 | 2018-10-20 | ||
US10160750B2 (en) | 2015-06-19 | 2018-12-25 | Bristol-Myers Squibb Company | Diamide macrocycles as factor XIa inhibitors |
CN114805365B (zh) | 2015-07-29 | 2024-07-23 | 百时美施贵宝公司 | 携带非芳族p2′基团的因子xia新大环 |
JP6785838B2 (ja) | 2015-08-05 | 2020-11-18 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 新規な置換グリシン誘導のfxia阻害剤 |
JP2019507167A (ja) | 2016-03-02 | 2019-03-14 | ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company | 第xia因子阻害活性を有するジアミド大員環 |
WO2017152126A1 (fr) | 2016-03-03 | 2017-09-08 | Cornell University | Inhibiteurs ire1-alpha à petites molécules |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994002477A1 (fr) | 1992-07-24 | 1994-02-03 | Merck Sharp & Dohme Limited | Derives d'imidazole, de triazole et de tetrazole |
US5317103A (en) | 1991-01-15 | 1994-05-31 | Merck Sharp & Dohme Limited | Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists |
WO1995013155A1 (fr) | 1993-11-08 | 1995-05-18 | Ishikawajima-Harima Heavy Industries Company Limited | Traitement thermique en ligne d'un feuillard d'acier coule en continu |
US9607692B2 (en) | 2014-10-03 | 2017-03-28 | Micron Technology, Inc. | Threshold voltage distribution determination |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL104311A (en) * | 1992-02-05 | 1997-07-13 | Fujisawa Pharmaceutical Co | Pyrazole derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same |
US5612378A (en) * | 1995-06-06 | 1997-03-18 | 3-Dimensional Pharmaceuticals, Inc. | Bis-arylsulfonylaminobenzamide derivatives and the use thereof as factor Xa inhibitors |
US5612353A (en) * | 1995-06-07 | 1997-03-18 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted (sulfinic acid, sulfonic acid, sulfonylamino or sulfinylamino) N-[(aminoiminomethyl)phenylalkyl]-azaheterocyclylamide compounds |
DE19530996A1 (de) * | 1995-08-23 | 1997-02-27 | Boehringer Mannheim Gmbh | Cyclische Guanidine, Verfahren zu ihrer Herstellung und Arzneimittel |
ATE267011T1 (de) * | 1995-12-21 | 2004-06-15 | Bristol Myers Squibb Pharma Co | Isoxazolin, isothiazolin und pyrazolin als faktor xa inhibitoren |
US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
-
1998
- 1998-06-17 ZA ZA9805247A patent/ZA985247B/xx unknown
- 1998-06-18 EA EA200000047A patent/EA003210B1/ru not_active IP Right Cessation
- 1998-06-18 IL IL13352598A patent/IL133525A0/xx active IP Right Grant
- 1998-06-18 SI SI9820044A patent/SI20160B/sl not_active IP Right Cessation
- 1998-06-18 MY MYPI98002740A patent/MY119820A/en unknown
- 1998-06-18 PL PL337756A patent/PL192941B1/pl not_active IP Right Cessation
- 1998-06-18 DE DE69831238T patent/DE69831238T2/de not_active Expired - Lifetime
- 1998-06-18 NZ NZ502370A patent/NZ502370A/xx unknown
- 1998-06-18 AT AT98930361T patent/ATE302198T1/de not_active IP Right Cessation
- 1998-06-18 HR HR08/878,884A patent/HRP980333A2/hr not_active Application Discontinuation
- 1998-06-18 HU HU0002686A patent/HUP0002686A3/hu unknown
- 1998-06-18 AU AU79768/98A patent/AU756755B2/en not_active Ceased
- 1998-06-18 BR BR9810137-4A patent/BR9810137A/pt not_active Application Discontinuation
- 1998-06-18 ES ES98930361T patent/ES2244064T3/es not_active Expired - Lifetime
- 1998-06-18 UA UA99105577A patent/UA57780C2/uk unknown
- 1998-06-18 EE EEP199900583A patent/EE04153B1/xx not_active IP Right Cessation
- 1998-06-18 RO RO99-01317A patent/RO120543B1/ro unknown
- 1998-06-18 KR KR1019997012030A patent/KR100546522B1/ko not_active IP Right Cessation
- 1998-06-18 JP JP50478599A patent/JP4319255B2/ja not_active Expired - Fee Related
- 1998-06-18 EP EP98930361A patent/EP0991638B1/fr not_active Expired - Lifetime
- 1998-06-18 DK DK98930361T patent/DK0991638T3/da active
- 1998-06-18 WO PCT/US1998/012680 patent/WO1998057951A1/fr active IP Right Grant
- 1998-06-18 CN CNB988060515A patent/CN100358888C/zh not_active Expired - Fee Related
- 1998-06-18 CA CA002291442A patent/CA2291442A1/fr not_active Abandoned
- 1998-06-18 SK SK1728-99A patent/SK285685B6/sk not_active IP Right Cessation
- 1998-06-19 AR ARP980102938A patent/AR015391A1/es active IP Right Grant
- 1998-08-19 TW TW087109910A patent/TW544453B/zh not_active IP Right Cessation
-
1999
- 1999-12-03 NO NO19995965A patent/NO318359B1/no not_active IP Right Cessation
- 1999-12-14 IL IL133525A patent/IL133525A/en not_active IP Right Cessation
- 1999-12-16 LV LVP-99-178A patent/LV12496B/en unknown
- 1999-12-17 LT LT99-147A patent/LT4705B/lt not_active IP Right Cessation
-
2000
- 2000-12-14 HK HK00108049A patent/HK1028606A1/xx not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5317103A (en) | 1991-01-15 | 1994-05-31 | Merck Sharp & Dohme Limited | Indole-substituted five-membered heteroaromatic compounds as 5-HT1 agonists |
WO1994002477A1 (fr) | 1992-07-24 | 1994-02-03 | Merck Sharp & Dohme Limited | Derives d'imidazole, de triazole et de tetrazole |
WO1995013155A1 (fr) | 1993-11-08 | 1995-05-18 | Ishikawajima-Harima Heavy Industries Company Limited | Traitement thermique en ligne d'un feuillard d'acier coule en continu |
US9607692B2 (en) | 2014-10-03 | 2017-03-28 | Micron Technology, Inc. | Threshold voltage distribution determination |
Non-Patent Citations (1)
Title |
---|
R. R. TIDWELL ET AL.: "Diarylamidine derivatives with one or both of the aryl moieties consisting of an indole or indole-like ring. Inhibitors of arginine-specific esteroproteases", J. MED. CHEM., 1978, pages 613 - 623, XP000573913, DOI: doi:10.1021/jm00205a005 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
LT4705B (lt) | Nauji guanidininiai imitatoriai kaip xa faktoriaus inhibitoriai | |
US6339099B1 (en) | Guanidine mimics as factor Xa inhibitors | |
US6602895B2 (en) | Inhibitors of factor Xa with a neutral P1 specificity group | |
US6271237B1 (en) | Nitrogen containing heteromatics with ortho-substituted P1s as factor Xa inhabitors | |
EP0991625B1 (fr) | INHIBITEURS DU FACTEUR Xa COMPRENANT UN GROUPE A SPECIFICITE P1 NEUTRE | |
SI20017A (sl) | Dušik vsebujoči heteroaromati kot inhibitorji faktorja Xa | |
JP2001526268A (ja) | Xa因子阻害剤としての、オルト−置換P1を有する、窒素含有複素環式芳香族化合物 | |
US6548512B1 (en) | Nitrogen containing heteroaromatics as factor Xa inhibitors | |
CZ442099A3 (cs) | Nové guanidinové deriváty jako inhibitory faktoru Xa | |
LT4702B (lt) | Xa faktoriaus inhibitorius su neutralia p1 specifine grupe | |
CZ444399A3 (cs) | Inhibitory faktoru Xa s neutrální Pl skupinovou specifičností | |
LT4673B (lt) | Azoto heteroaromatiniai junginiai kaip faktoriaus xa inhibitoriai |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PD9A | Change of patent owner |
Free format text: 20020712 * BRISTOL-MYERS SQUIBB PHARMA COMPANY,US |
|
MM9A | Lapsed patents |
Effective date: 20070618 |